The Effect of stemcell treatment on nephrotoxicity developing after cyclophosphamide treatment

The Effect of stemcell treatment on nephrotoxicity developing after cyclophosphamide treatment | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article The Effect of stemcell treatment on nephrotoxicity developing after cyclophosphamide treatment Muzaffer Çaydere, Aytaj Jafarzade, Feyza Bayrakdar Çağlayan, Elvan Anadol, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7124194/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Objectives This study examines the effects of cyclophosphamide, a cancer treatment that also functions as a cytotoxic agent, on the nephrotic system. The extent to which stem cell applications can be effective in preventing nephrotoxicity caused by agents is also a subject of investigation. The extent to which the nephrotoxic effects detected in the animal model treated with cyclophosphamide can be prevented by stem cell application will be investigated. Material and Methods A total of 18 Sprague Dawley rats were included in the study, divided into 3 groups. Group 1 consisted of the control group, which received intraperitoneal (IP) saline injection. Group 2-cyclophosphamide and Group 3-cyclophosphamide + stem cell was administered IP cyclophosphamide (50 mg/kg cyclophosphamide on the first day and then 8 mg/kg intraperitoneally for 14 days) to create a nephrotoxicity model. Group 3-cyclophosphamide + stem cell also received weekly hUCMSC 10*6 IP for 2 weeks. 4 weeks after the treatment, the animals were euthanized, their kidney tissues were histopathologically and immunohistochemically evaluated, and their blood values ​​were biochemically evaluated. Result In histopathological examination, glomerulosclerosis and tubular damage were seen the most in Group 2, and this difference was found to be statistically significant (p<0.001 and p<0.01). However, no statistically significant difference was observed in terms of inflammation in the kidney tissues (p=0.068). No significant change was observed in the biochemically evaluated BUN, creatinine, or urea levels in all three groups (p<0.8; p<0.141; p<0.8). Conclusion In light of the current information, human Umbilical Cord Mesenchymal Stem Cell (hUC-MCS) has been demonstrated to reduce the nephrotoxicity caused by cyclophosphamide given for cytotoxic purposes on the kidney and exhibit regenerative effects. Our findings create new hope for the use of stem cell therapies in the field of kidney diseases. Figures Figure 1 Figure 2 Introduction Cyclophosphamide (CTX) is widely used in cancer treatment and has many side effects, primarily nephrotoxicity and hepatotoxicity (1). Today, cyclophosphamide is widely used as a chemotherapeutic agent, alone or in combination. It is used as an immunosuppressant especially in acute and chronic leukemias; ovarian cancers; multiple myeloma; lymphoma; testicular, small cell lung, and breast cancers; as well as organ transplantation; rheumatoid arthritis; systemic lupus erythematosus; and multiple sclerosis (2,3). The two active metabolites of cyclophosphamide are phosphoramide mustard and acrolein. The antineoplastic effects of cyclophosphamide are related to phosphoramide mustard. It is thought that phosphoramide mustard suppresses cell division by binding to DNA and mediating the immunosuppressive and antitumor effects of cyclophosphamide. The toxic effect of cyclophosphamide is related to its active metabolite, acrolein (4). Acrolein inhibits P-450 by alkylating sulfhydryl groups (5) and metabolizing glutathione via rapid modification of sulfhydryl groups to form mercapturic acid, which is excreted in urine (6). These metabolites cause both hepatic and renal damage. The renal pathological damage process caused by CTX is mediated by apoptosis and necrosis of renal tubular epithelial cells (7), release of inflammatory factors, and inflammatory response (8). Stem cells are cells that can self-renew, differentiate into multiple cell types, and proliferate to produce and renew different types of tissues and organs. Stem cells are used in the treatment of many diseases (5) (6,7). In addition, stem cell transplantation is performed after CTX in some cancer treatment protocols (8). While research has explored strategies for the treatment of both hepatotoxicity (9,10,11) and nephrotoxicity (12,13,14), we have not come across any reports investigating the efficacy of stem cell therapies in cyclophosphamide treatment. Stem cell therapies are used after cyclophosphamide in the treatment protocol of some cancer diseases (15). In addition, stem cells have paracrine effects by promoting their differentiation capacity into other cells and generating immune regulatory, anti-inflammatory, anti-apoptotic, and anti-oxidative effects (16,17). Stem cells also have analgesic and angiogenic effects (18). Due to the regeneration properties of stem cells, damaged tissues can be renewed and repaired. In this study, we aimed to investigate the efficacy of umbilical cord-derived mesenchymal stem cells in animals with renal damage induced by CTX. Materials and Methods Formation of cyclophosphamide-induced kidney injury model and administration of h-USMSC. A total of 18 female Sprague Dawley rats that were 9–10 weeks old and weighed 200–220 g were used in the study. The animals were obtained from the Gazi University Laboratory Animal Breeding and Experimental Research Centre and studied in the same laboratory. The study was approved by the Gazi University Animal Experiments Local Ethics Committee (Approval number: G.Ü.E.T-66332047-604.01-1015251). The animals were randomly divided into 3 groups. Group 1 (control group) received 2 cc 0.9% saline infusion intraperitoneally. For the liver and kidney injury models, Groups 2 and 3 were injected with 50 mg/kg cyclophosphamide (Endoxan, EIP ECZACIBAŞI, Istanbul, Turkey) on the first day, and then 8 mg/kg intraperitoneal cyclophosphamide (CTX) was injected into the animals for 14 days. Group 3 was then injected with 0.6ml×10 5 /μL human Umbilical Cord Mesenchymal Stem Cell (hUC-MCS) intraperitoneally once a week for 2 weeks. At the end of the 4th week of the experiment, animals were euthanized by intracardiac blood sampling under xylazine (5 mg/kg, i.m) and ketamine (45 mg/kg, i.m) anesthesia. Kidney and liver tissues were then removed and fixed in formaldehyde. Histological examination of rat kidneys Kidneys were fixed with 4% paraformaldehyde and embedded in paraffin for pathological analysis. Paraffin blocks were cut into 4-μm thick sections and stained with hematoxylin and eosin (H&E) and caspase. Elisa Whole blood samples from the study groups were centrifuged at 3500 rpm for 10 minutes to separate the sera. Humor samples were stored in a -80◦C deep freezer until the day of the study together with aqueous humor samples. Serum samples were measured using the BT Lab (Zhejiang, China) brand kit using the sandwich ELISA principle. The experiment was performed according to the instructions of the commercial kit. A standard graph was drawn according to the absorbance in the standard samples, and the absorbance values read in the samples were substituted into this graph to calculate the concentrations. Kidney function evaluation To evaluate kidney function, BUN (blood urea nitrogen), urea, and creatinine levels were checked at 6 weeks in Groups 1, 2 and 3. Histopathologically, the degree of tubular atrophy was examined at four stages (0–25%, 25–50%, 50–75%, and 75–100%) and scored between 0–3. The presence of glomerulosclerosis was divided into 4 stages (0-25%, 25-50%, 50-75%, and 75-100%) and scored between 0–3 according to the percentage of presence in the examined area. Those with and without inflammation were graded as 0 and 1, respectively. Statistical Analysis In this study, the studied data set was statistically compared among three different separate groups based on specific measurement criteria. The Kruskal-Wallis analysis of variance was done to evaluate differences in measurement parameters between group levels. If a difference existed, the Dunnett method was used to determine pairwise comparisons of group levels. The test's critical value was 0.05, and a p-value greater than 0.05 indicated that there was no significant difference between variables. The variables examined in the study glomerulosclerosis, tubal damage, and inflammation are categorical in nature, and their distributions were compared across three different groups (Control, CTX, and CTX + stem cell). These variables typically have between 2 to 4 levels and exhibit ordinal categorical structure (e.g., scores ranging from 0 to 3). Due to the relatively small sample sizes in each group and the presence of expected cell frequencies below 5 in some contingency tables, the assumptions of the chi-square test could not be met. Therefore, the Fisher’s Exact Test, a more appropriate and sensitive alternative for small sample sizes, was used to assess group differences. Otherwise, a statistical significance was measured between the variables. All analyses were conducted using the R programming language. Results When BUN, creatinine, and urea levels were evaluated biochemically in the three groups, no significant change was observed (Table 1). In histopathological evaluation, in the Group 1 control group, 3 samples (60%) showed Stage 0 and 2 samples (40%) showed Stage 1 glomerulosclerosis. In the Group 2 cyclophosphamide group, 4 samples (80%) showed Stage 2 and 1 sample (20%) showed Stage 3 glomerulosclerosis. In the Group 3 cyclophosphamide + stem cell therapy group, 5 samples (100%) showed Stage 1 glomerular sclerosis, and the difference was statistically significant (p<0.001). When tubular atrophy was evaluated, in Group 1, 2 samples (40%) showed Stage 0 and 3 samples (60%) showed Stage 1. In Group 2, 3 samples (60%) showed Stage 2 and 2 samples (40%) showed Stage 3. In Group 3, 4 samples (80%) were detected as Stage 1 and 1 sample (20%) as Stage 2. The observed differences were statistically significant (p=0.010). The presence of inflammation was observed in 2 samples (40%) in Group 1, 5 samples (100%) in Group 2 and 1 sample (20%) in Group 3 and was significantly lower in Group 3. However, this difference was not statistically significant (p=0.068) (Table 2). Histopathological comparison was made between Group 1-control, Group 2-CTX and Group 3-CTX+ stem cell included in the study. In histopathological examination, normal shapes and structures were seen in all areas of the kidney tissues in Group 1. In Group 2, glomeruli shrinkage, Bowman space widening, dilatation, degeneration, and epithelial vacuolization in tubules were observed. In addition, moderate inflammation was observed throughout the entire section. In Group 3, serious regeneration was observed in all areas of the kidney tissue, including an improvement in Bowman spaces; tubular dilatation, epithelial degeneration and vacuolization were also observed to significantly decrease. In caspase-3 staining, normal findings were detected in Group 1, while increased staining was observed in glomeruli and tubular structures in Group 2. In Group 3, a high rate of tubular and glomerular regeneration was observed (Figure 1). Glomerulosclerosis and tubular damage were seen most in Group 2, and this difference was found to be statistically significant (p<0.001; p<0.01) Figure 2. Discussion Since the metabolism enzymes of many drugs are located in the kidneys, these organs are where these agents are excreted from the body and can therefore show toxicity. Cyclophosphamide (CTX) is a drug generally used in chemotherapy, and its metabolites are primarily excreted in the urine. Therefore, it is known that CTX can be toxic to the kidneys. CTX delays the growth of malignant cells due to its toxic metabolites phosphoramide and acrolein. Acrolein inhibits the cellular antioxidant defense cycle and causes the formation of reactive oxygen radicals, including superoxide anions, hydroxyl radicals, and hydrogen peroxide, which cause physiological and morphological changes (19). The formation of free radicals causes the disruption of many signaling pathways, including the inflammation pathway and ultimately organ fibrosis (20). This situation has led to the hypothesis that the effects of CTX can be reduced using antioxidant agents. It is known that the mutagenic and cytotoxic effects of cyclophosphamide are specific to proliferating cells only, and that quiescent cells are relatively protected by damage detection mechanisms. However, cyclophosphamide is known to cause severe side effects in high doses and/or long-term use. In today's nephrology practice, the use of CTX has been significantly restricted. However, it is still used as a steroid-reducing drug in minimal change disease and focal segmental glomerulosclerosis, both in combination with steroids in membranous glomerulonephritis and as the first choice in rapidly progressive glomerulonephritis and certain lupus patients. It is generally recommended to avoid long-term use (21). Although there are restrictions on its use in nephrology practice, cyclophosphamide is used in the treatment of many malignancies. Since significant beneficial effects are observed in allogeneic or autologous stem cell transplantation applied after cyclophosphamide treatment, the question of whether it may have similar effects on damaged kidney tissues has emerged. As in tumors, damaged tissues secrete various factors that attract stem cell migration via the CXCL12/CXCR4 axis. Factors that promote stem cell migration include interleukin 8 (IL-8) and transforming growth factor-beta 1 (TGF-β1) (22), platelet-derived growth factor (PDGF) (23), fibroblast growth factor 2 (FGF-2) (24), vascular endothelial growth factor (VEGF) (24), and extracellular matrix molecules such as matrix metalloproteinase-2 (MMP-2) (25). The primary reparative mechanisms of stem cells include paracrine effects such as angiogenesis (26), anti-apoptosis (26), anti-fibrosis (27), and immunomodulation (28). It is known that exosomes, which are vesicles derived from stem cells that are 30 to 160 nm in size, play an important role in regulating intercellular communication (29). It is also known that stem cells have the potential to replace damaged mitochondria in damaged cells and increase cell quality (30), therefore their healing effects on damaged tissues were examined in our study. The differences between kidney function tests in the samples were first evaluated. However, no significant difference was found between the groups in terms of BUN, urea, or creatinine levels. It is thought that this situation may be because these markers were measured at the 6th week. In similar studies, kidney functions were evaluated in rats given CTX in a shorter period of time. For example, in Uygun et al., kidney function tests were measured 24 hours after cyclophosphamide administration, and significant increases in creatinine and urea were observed in the CTX arm (31). In a similar study, the protective effects of tolvaptan on CTX treatment were investigated; blood samples were taken one day after CTX administration, and significant increases in creatinine and urea were observed in the CTX arm (32). In a study aiming to reduce the effects of high-dose CTX treatment, the effects of Wuzhi capsules on treatment were investigated; once again, as blood samples were taken at an early stage, urea and creatinine values were found to be significantly higher in the CTX group compared to the control group (33). In many similar studies, urea and creatinine were observed to be significantly higher in the CTX groups compared to the control groups in the samples taken immediately after the completion of the experiment (34,35,36,37). In a study where creatinine, BUN, and urea were measured on the 25th day of cyclophosphamide administration, kidney function tests were found to be significantly higher in the CYS arm (38). In our study, taking the samples at the 6th week made a difference in terms of providing information on the late effects of cyclophosphamide on kidney functions. Although BUN, creatinine, and urea levels were higher in the cyclophosphamide arm at the end of the 6th week, this increase was not statistically significant. This situation can be explained by the fact that the acute kidney injury picture started to improve in rats that had experienced an acute kidney injury when there was no repeated dosing. To observe organ integrity in the event of any damage, pathological indicators can be shown by the deterioration of the structural integrity and shape of the organ. It is known that cyclophosphamide directly induces oxidative stress, causes apoptosis and inflammation, and leads to histopathological conditions (39). In our study, via hematoxylin-eosin staining, renal integrity was seen to be impaired: There was shrinkage in the glomeruli, widening in the Bowman spaces, dilatation in the renal tubules, and vacuolization in the epithelium and degeneration, especially in the renal tubules. In addition, moderate inflammation was observed in all sections. The findings are also consistent with previous studies (19,33,34,35,36). In the group that received stem cell application with the aim of repairing effects on damaged tissues, significant regeneration was observed in the hematoxylin and eosin-stained sections. There was an improvement in glomerular Bowman spaces; and tubular dilatation, epithelial degeneration, and vacuolization had significantly lessened. Apoptosis, which is a cell collapse characterized by condensation of the cell membrane, shrinkage of the cell, condensation of chromatin and fragmentation of DNA, occurs as a result of reactive oxygen radicals (40, 41). Caspase-3 is considered the main mediator of apoptosis in cells because it initiates the apoptotic process by activating other caspase enzymes, causing fragmentation of DNA and protein structures and condensation of chromatin (42). In our study, while a normal appearance was detected with caspase staining in the control group, a significantly increased uptake in glomerular and tubular structures was observed in the CTX group, and tubular and glomerular regeneration was observed in the CTX+stem cell group. This situation was observed in our study, similar to existing studies (19, 42, 43). Today, hUC-MCS is used in the treatment of diseases with nephropathy, such as diabetes mellitus and systemic lupus erythematosus. When applied in the treatment of diabetic nephropathy, it has been observed to reduce the expression of inflammatory cytokines; increase the number of Sertoli cells and rearrange their proteins; and increase the expression of anti-apoptotic proteins in the kidneys (44). In studies conducted in diabetic mice, it has been observed that BUN and 24-hour urine albumin excretion significantly decrease after hUC-MCS application (45). In lupus nephritis, it is thought that hUC-MCS migration to the kidney is accelerated by CXCL10 synthesized by increased glomerular vascular endothelial cells via the FN-γ/IRF1-KPNA4 pathway. The negative effect of therapeutic effects on the blockade of the CXCL10-CXCR3 pathway also supports this view (46). It has also been shown that hUC-MCSs improve lupus nephritis by affecting T and B cell responses (47). The use of hUC-MCS treatment in diseases with nephropathy and its beneficial effects shed light on its use in primary and secondary nephropathies. The waste material, a human umbilical cord, was obtained non-invasively; the lack of ethical issues provides an advantage over other sources of stem cells. In addition, the neonatal age of the donor creates a difference in terms of stem cell potency. In our study, it was observed that cyclophosphamide improved the pathological effects and provided significant morphological improvement. These findings suggest that its use in drug-related nephropathies may be beneficial, indicating that it may be worth trying in other nephrological diseases. The factors affecting the results of the study include the reparative effects of the stem cells administered for therapeutic purposes on the kidney tissue, the duration and frequency of treatment, the number of cells administered for therapeutic purposes, the selected stem cell source, and even the donor selection. Another factor affecting the results is the time elapsed after administration of the stem cell treatment. Changes in kidney tissue after stem cell transplantation may also vary depending on the time of euthanasia. We believe that these factors explain the different results among studies to some extent. Therefore, more studies are needed. Conclusion Permanent organ damage due to cytotoxic agents used for different purposes has the potential to create serious problems in the future. In this context, the possible nephrotoxic effects of cyclophosphamide, which is used in many cancer treatments, were examined in this study and shown to cause pathologies resulting in glomerulosclerosis and tubular damage. Although no early deviations were detected in laboratory parameters considered as clinical indicators, it is possible that possible failures may occur in the long term. In this context, it has been shown that stem cell applications given together reduce the formation of glomerulosclerosis and tubular damage, and it is thought that this effect may be effective in long-term survival. In the future, it can be expected that these applications will be beneficial in terms of effectiveness within classical protocols in cost-effectiveness studies. Declarations Conflict of Interest: There is no conflict of interest between the authors. All authors read and approved the final version of the manuscript Attestation Statement: Animal experiment study Funding: No funding. Compliance with Ethical Standards: Written approval from the Gazi University Ethics Committee, was obtained for the study. The study was approved by Gazi University Animal Experiments Local Ethics Committee (Approval number: G.Ü.E.T-66332047-604.01-1015251). All authors have approved the manuscript submission, and the manuscript has not been published. It is not being considered for publication elsewhere, in whole or in part, in any language. All data generated or analysed during this study are included in this published article and its supplementary information files and the datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Consent for Publication : Not Applicable Author contribution. Muzaffer ÇAYDERE- Pathological examination of tissues and Data collection writer Aytaj JAFARZADE, -Conception, design,writer , supervision, literature review Feyza Bayrakdar Çağlayan- Conception, design,writer , supervision, literature review Elvan ANADOL - Animal prosessing and data collection Durmuş BURGUCU- Preparation and application of hucMSCs and Data collection Canan YILMAZ- Study and analysis of blood samples and Data Collection Semih ERGİŞİ - Statistical analysis and interpretation Tamer M. MUNGAN - Critical reviewing References Jiang X, Ren Z, Zhao B, Zhou S, Ying X, Tang Y. Ameliorating Effect of Pentadecapeptide Derived from Cyclina sinensis on Cyclophosphamide-Induced Nephrotoxicity. Mar Drugs. 2020 Sep 9;18(9):462. doi: 10.3390/md18090462. Perini P, Calabrese M, Rinaldi L, Gallo P (2007) The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opin Drug Saf 6:183–190 Uber WE, Self SE, Van Bakel AB, Pereira NL (2007) Acute antibody-mediated rejection following heart transplantation. Am J Transplant 7:2064–2074 Cengiz M, Yeşildağ Ö, Ayhancı A. Siklofosfamid Nedenli Hematoksisite Üzerine Karvakrolün Sitoprotektif Etkileri. TÜTAD. Haziran 2018;5(2):125-130. doi:10.19159/tutad.378717 Zarei, Mahsa, and T. Shivanandappa. "Amelioration of cyclophosphamide-induced hepatotoxicity by the root extract of Decalepis hamiltonii in mice." Food and chemical toxicology 57 (2013): 179-184. Mohammad, Mohammad K., et al. "Acrolein cytotoxicity in hepatocytes involves endoplasmic reticulum stress, mitochondrial dysfunction and oxidative stress." Toxicology and applied pharmacology 265.1 (2012): 73-82. Rehman MU, Tahir M, Ali F, Qamar W, Lateef A, Khan R, Quaiyoom A, Oday-O-Hamiza, Sultana S. Cyclophosphamide-induced nephrotoxicity, genotoxicity, and damage in kidney genomic DNA of Swiss albino mice: the protective effect of Ellagic acid. Mol Cell Biochem. 2012 Jun;365(1-2):119-27. Kang X, Jing M, Zhang G, He L, Hong P, Deng C. The Ameliorating Effect of Plasma Protein from Tachypleus tridentatus on Cyclophosphamide-Induced Acute Kidney Injury in Mice. Mar Drugs. 2019 Apr 15;17(4):227 Cuce G, Çetinkaya S, Koc T, Esen HH, Limandal C, Balcı T, Kalkan S, Akoz M. Chemoprotective effect of vitamin E in cyclophosphamide-induced hepatotoxicity in rats. Chem Biol Interact. 2015 May 5;232:7-11. doi: 10.1016/j.cbi.2015.02.016. Nafees S, Rashid S, Ali N, Hasan SK, Sultana S. Rutin ameliorates cyclophosphamide induced oxidative stress and inflammation in Wistar rats: role of NFκB/MAPK pathway. Chem Biol Interact. 2015 Apr 25;231:98-107. doi: 10.1016/j.cbi.2015.02.021. Mohammed MJ, Tadros MG, Michel HE. Geraniol protects against cyclophosphamide-induced hepatotoxicity in rats: Possible role of MAPK and PPAR-γ signaling pathways. Food Chem Toxicol. 2020 May;139:111251. doi: 10.1016/j.fct.2020.111251 Liu Q, Lin X, Li H, Yuan J, Peng Y, Dong L, Dai S. Paeoniflorin ameliorates renal function in cyclophosphamide-induced mice via AMPK suppressed inflammation and apoptosis. Biomed Pharmacother. 2016 Dec;84:1899-1905 Shi M, Pei H, Sun L, Chen W, Zong Y, Zhao Y, Du R, He Z. Optimization of the Flavonoid Extraction Process from the Stem and Leaves of Epimedium Brevicornum and Its Effects on Cyclophosphamide-Induced Renal Injury. Molecules. 2023 Dec 29;29(1):207. Pramita Chakraborty, Ugir Hossain Sk, et al. "Modulation of cyclophosphamide-induced cellular toxicity by diphenylmethyl selenocyanate in vivo, an enzymatic study." J Journal of Cancer Molecules 4.6 (2009): 183-189. Wei X, Wei Y. Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments. Ann Hematol. 2023 May;102(5):995-1009. Brown C, McKee C, Bakshi S, Walker K, Hakman E, Halassy S, Svinarich D, Dodds R, Govind CK, Chaudhry GR. Mesenchymal stem cells: Cell therapy and regeneration potential. J Tissue Eng Regen Med. 2019 Sep;13(9):1738-1755. doi: 10.1002/term.2914. Han Y, Li X, Zhang Y, Han Y, Chang F, Ding J. Mesenchymal Stem Cells for Regenerative Medicine. Cells. 2019 Aug 13;8(8):886. doi: 10.3390/cells8080886. Erceg Ivkošić I, Fureš R, Ćosić V, Mikelin N, Bulić L, Dobranić D, Brlek P, Primorac D. Unlocking the Potential of Mesenchymal Stem Cells in Gynecology: Where Are We Now? J Pers Med. 2023 Aug 13;13(8):1253. Caglayan C, Temel Y, Kandemir FM, Yildirim S, Kucukler S. Naringin protects against cyclophosphamide-induced hepatotoxicity and nephrotoxicity through modulation of oxidative stress, inflammation, apoptosis, autophagy, and DNA damage. Environ Sci Pollut Res Int . 2018;25(21):20968-20984. doi:10.1007/s11356-018-2242-5 Meng X.-M., Nikolic-Paterson D. J., Lan H. Y. Inflammatory processes in renal fibrosis. Nature Reviews Nephrology . 2014;10(9):493–503. doi: 10.1038/nrneph.2014.114.) Ponticelli, C., Escoli, R., & Moroni, G. (2018). Does cyclophosphamide still play a role in glomerular diseases?. Autoimmunity Reviews , 17 (10), 1022-1027 de Araujo Farias V, Carrillo-Galvez AB, Martin F, Anderson P. TGF-beta and mesenchymal stromal cells in regenerative medicine, autoimmunity and cancer. Cytokine Growth Factor Rev. 2018;43:25–37. doi: 10.1016/j.cytogfr.2018.06.002 Ding W, et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood. 2010;116:2984–2993. doi: 10.1182/blood-2010-02-269894 . Ritter E, et al. Breast cancer cell-derived fibroblast growth factor 2 and vascular endothelial growth factor are chemoattractants for bone marrow stromal stem cells. Ann. Surg. 2008;247:310–314. doi: 10.1097/SLA.0b013e31816401d5 . C ronwright G, et al. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res. 2005;65:2207–2215. doi: 10.1158/0008-5472.CAN-04-188 Teng X, Wang Z, Wang X. Enhancing angiogenesis and inhibiting apoptosis: evaluating the therapeutic efficacy of bone marrow mesenchymal stem cell-derived exosomes in a DHEA-induced PCOS mouse model. J Ovarian Res. 2024 Jun 5;17(1):121. doi: 10.1186/s13048-024-01445-w. Vanderstichele S, Vranckx JJ. Anti-fibrotic effect of adipose-derived stem cells on fibrotic scars. World J Stem Cells. 2022 Feb 26;14(2):200-213. doi: 10.4252/wjsc.v14.i2.200. Li J, Wu M, He L. Immunomodulatory effects of mesenchymal stem cell therapy in chronic kidney disease: a literature review. BMC Nephrol. 2025 Mar 3;26(1):107. doi: 10.1186/s12882-025-04029-y. Tan F, Li X, Wang Z, Li J, Shahzad K, Zheng J. Clinical applications of stem cell-derived exosomes. Signal Transduct Target Ther. 2024 Jan 12;9(1):17. doi: 10.1038/s41392-023-01704-0. Zhang, C., Meng, Y. & Han, J. Emerging roles of mitochondrial functions and epigenetic changes in the modulation of stem cell fate. Cell. Mol. Life Sci. 81, 26 (2024). https://doi.org/10.1007/s00018-023-05070-6 Uyumlu AB, Satılmış B, Atıcı B, Taşlıdere A. Phenethyl isothiocyanate protects against cyclophosphamide-induced nephrotoxicity via nuclear factor E2-related factor 2 pathway in rats. Exp Biol Med (Maywood). 2023 Jan;248(2):157-164. El‐Shabrawy, M., Mishriki, A., Attia, H., Emad Aboulhoda, B., Emam, M., & Wanas, H. (2020). Protective effect of tolvaptan against cyclophosphamide‐induced nephrotoxicity in rat models. Pharmacology Research & Perspectives , 8 (5), e00659. Chen, L., Xiong, X., Hou, X., Wei, H., Zhai, J., Xia, T., ... & Chen, W. (2019). Wuzhi capsule regulates chloroacetaldehyde pharmacokinetics behaviour and alleviates high‐dose cyclophosphamide‐induced nephrotoxicity and neurotoxicity in rats. Basic & Clinical Pharmacology & Toxicology , 125 (2), 142-151. Mohsin N, Akhtar MS, Alkahtani SA, et al. Nephroprotective Effect of Bergapten Against Cyclophosphamide-Mediated Renal Stress, Inflammation, and Fibrosis in Wistar Rats: Probable Role of NF-kB and TGF-β1 Signaling Molecules. ACS Omega. 2024 Apr 12;9(16):18296-18303. Salama, R. M., Nasr, M. M., Abdelhakeem, J. I., Roshdy, O. K., & ElGamal, M. A. (2022). Alogliptin attenuates cyclophosphamide-induced nephrotoxicity: a novel therapeutic approach through modulating MAP3K/JNK/SMAD3 signaling cascade. Drug and Chemical Toxicology , 45 (3), 1254-1263. Gunes, S., Sahinturk, V., Uslu, S., Ayhanci, A., Kacar, S., & Uyar, R. (2018). Protective effects of selenium on cyclophosphamide-induced oxidative stress and kidney injury. Biological trace element research , 185 , 116-123. Wanas, H., El‐Shabrawy, M., Mishriki, A., Attia, H., Emam, M., & Aboulhoda, B. E. (2021). Nebivolol protects against cyclophosphamide‐induced nephrotoxicity through modulation of oxidative stress, inflammation, and apoptosis. Clinical and Experimental Pharmacology and Physiology , 48 (5), 811-819.) Alsaidi, Z. Z., Humaish, H. H., & Alasadi, A. (2022). Toxic effects of cyclophosphamide on hepatic and kidney tissues in albino mice model. Research Journal of Pharmacy and Technology , 15 (10), 4655-4659.) Cetinavci D.; Yenilmez D.; Yenilmez E.; Firuze Bıyık A.; Alver A.; Sağlam N. Rosmarinik asidin sıçanlarda siklofosfamid ile indüklenen nefrotoksisite üzerine etkileri. Cukurova Med. J. 2023, 48 (3), 902–910. 10.17826/CUMJ.1317508. Renehan AG, Booth C, Potten CS. What is apoptosis, and why is it important? BMJ. 2001 Jun 23;322(7301):1536-8. doi: 10.1136/bmj.322.7301.1536. Kim S, Lee I, Baek H, et al. Mechanism for the protective effect of diallyl disulfide against cyclophosphamide acute urotoxicity in rats. Food Chem Toxicol. 2014;64:110-118. Fouad A, Qutub H, Al-Melhim W. Punicalagin alleviates hepatotoxicity in rats challenged with cyclophosphamide. Environ Toxicol Pharmacol. 2016;45:158-162 Sinanoglu O, Yener AN, Ekici S, Midi A, Aksungar FB (2012) The protective effects of spirulina in cyclophosphamide induced nephrotoxicity and urotoxicity in rats. Urology 80:1392–13e1. https:// doi.org/10.1016/j.urology.2012.06.053 Xiang E, Han B, Zhang Q, Rao W, Wang Z, Chang C, Zhang Y, Tu C, Li C, Wu D. Human umbilical cord-derivedmesenchymal stem cells prevent the progression of early diabetic nephropathythrough inhibiting inflammation and fibrosis. Stem Cell Res Ther. 2020;11(1):336–350. doi: 10.1186/s13287-020-01852-y.) Xian Y, Lin Y, Cao C, Li L, Wang J, Niu J, YunleiGuo YS, Wang Y, Wang W. Protective effect of umbilical cord mesenchymal stem cells combined with resveratrol against renal podocyte damage in NOD mice. Diabetes Res Clin Pract. 2019;156:107755–107764. doi: 10.1016/j.diabres.2019.05.034 Zhang, Q., Shan, Y., Shen, L., Ni, Q., Wang, D., Wen, X., Xu, H., Liu, X., Zeng, Z., Yang, J., Wang, Y., Liu, J., Su, Y., Wei, N., Wang, J., Sun, L., Wang, G., & Zhou, F. (2024). Renal remodeling by CXCL10-CXCR3 axis-recruited mesenchymal stem cells and subsequent IL4I1 secretion in lupus nephritis. Signal transduction and targeted therapy , 9 (1), 325. https://doi.org/10.1038/s41392-024-02018-5) Li, C., Wu, F., Mao, J., Wang, Y., Zhu, J., Hong, K., Xie, H., Zhou, X., Tian, J., & Wen, C. (2024). Mesenchymal stem cells-derived extracellular vesicles ameliorate lupus nephritis by regulating T and B cell responses. Stem cell research & therapy , 15 (1), 216. https://doi.org/10.1186/s13287-024-03834-w Tables Table 1 and 2 are available in the Supplementary Files section. Additional Declarations No competing interests reported. Supplementary Files table1.docx table2.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7124194","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":515054703,"identity":"18464156-047a-4a48-b3a5-a6b45bc3c8c9","order_by":0,"name":"Muzaffer Çaydere","email":"","orcid":"","institution":"Ankara Eğitim Araştırma Hastanesi","correspondingAuthor":false,"prefix":"","firstName":"Muzaffer","middleName":"","lastName":"Çaydere","suffix":""},{"id":515054705,"identity":"419b0ce5-8801-4085-bf8c-cca7eaecf215","order_by":1,"name":"Aytaj Jafarzade","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABFklEQVRIie2PsUrDUBSGT7iSLhfnhNLUFxBuuBB0ybM03KFLq4NLoIJn0kXMmr7FdXH1lIJdWrrGLVBw6hAQCkIRa1QUScgqeL/lHH7+j8MBMBj+IBZa+cf8DDwA3qQw8a0QgGxUAH4pETYp7GpqPcfbsJMAe2oX52FfzxaTvIDQO8RqxbpWzJ1zJcdoBw49qKGenyg/BSUDqvvllFx0WKQJdopNQ02DoM2Bors6JVmxFxQX0T21Ng69Ul8s1w1KqmwXe9NIAw+cySX1RNZ0JV3Zx0gzmRI/O1rcKH+craWfivpf/ESxR9yOOgm2brN4E3b3lwM/L+LQq1Xwa+vme877PCiborpeFn/srCgTrG4aDAbD/+UN9tRizwOq4QAAAAAASUVORK5CYII=","orcid":"","institution":"Liv hospital Ankara","correspondingAuthor":true,"prefix":"","firstName":"Aytaj","middleName":"","lastName":"Jafarzade","suffix":""},{"id":515054706,"identity":"dc7b23d0-a316-4bf0-84a1-8e94eaee6b02","order_by":2,"name":"Feyza Bayrakdar Çağlayan","email":"","orcid":"","institution":"Yuksek İhtisas University","correspondingAuthor":false,"prefix":"","firstName":"Feyza","middleName":"Bayrakdar","lastName":"Çağlayan","suffix":""},{"id":515054707,"identity":"f2cb9db5-d376-4f34-a3bf-04a4aa009172","order_by":3,"name":"Elvan Anadol","email":"","orcid":"","institution":"Gazi University, Emniyet","correspondingAuthor":false,"prefix":"","firstName":"Elvan","middleName":"","lastName":"Anadol","suffix":""},{"id":515054708,"identity":"af4d770f-49a9-4d22-925a-6c7adf399586","order_by":4,"name":"Durmuş Burgucu","email":"","orcid":"","institution":"stembio","correspondingAuthor":false,"prefix":"","firstName":"Durmuş","middleName":"","lastName":"Burgucu","suffix":""},{"id":515054709,"identity":"19d2af94-a241-42a9-979f-f1e4a005cc12","order_by":5,"name":"Canan Yılmaz","email":"","orcid":"","institution":"Gazi University, Emniyet","correspondingAuthor":false,"prefix":"","firstName":"Canan","middleName":"","lastName":"Yılmaz","suffix":""},{"id":515054710,"identity":"0754a606-d7b6-4cd9-9924-ae93a6bc8a85","order_by":6,"name":"Semih Ergişi","email":"","orcid":"","institution":"TÜBİTAK","correspondingAuthor":false,"prefix":"","firstName":"Semih","middleName":"","lastName":"Ergişi","suffix":""},{"id":515054711,"identity":"210d1c5d-2317-4439-89e1-f5e86ecd04ed","order_by":7,"name":"Tamer Mungan","email":"","orcid":"","institution":"Losante Hospital","correspondingAuthor":false,"prefix":"","firstName":"Tamer","middleName":"","lastName":"Mungan","suffix":""}],"badges":[],"createdAt":"2025-07-14 20:08:07","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7124194/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7124194/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":91999535,"identity":"22555712-6d5f-438f-bd8d-c68e30f92376","added_by":"auto","created_at":"2025-09-23 14:13:18","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":373530,"visible":true,"origin":"","legend":"\u003cp\u003eH\u0026amp;E staining of the kidney (orange arrows indicate renal tubules and black arrows glomeruli). 40×; scale bar = 40 μm.\u003c/p\u003e\n\u003cp\u003eA- H\u0026amp;E.a- Control group, b-CTX group, c-CTX+ Stem cell group. H\u0026amp;E staining results showed that CTX group rats exhibited abnormal renal structure, including glomerular shrinkage, renal tubule vacuolisation and hydrated renal tubule degeneration. In the CTX + Stem cell group, damage to glomeruli and renal tubules was significantly attenuated and exhibited regenerating morphology.\u003c/p\u003e\n\u003cp\u003eB- Caspase-3. Active caspase-3 positive cells, which is a marker for apoptosis. Cells with apaptosis are stained brown. a- Control group is observed in normal appearance, a high rate of tubular and glomerular apaptosis is observed in the b--CTX group and in c-CTX+ Stem cell group high rate of tubular and glomerular regeneration is observed.\u003c/p\u003e","description":"","filename":"1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-7124194/v1/bf17e028fd30b46e415cbfad.jpg"},{"id":91999536,"identity":"965a4dc9-2012-4c67-8cfb-a9c5e3ab5a43","added_by":"auto","created_at":"2025-09-23 14:13:18","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":5713,"visible":true,"origin":"","legend":"\u003cp\u003eIt was observed that there was increased glomerulosclerosis and tubular damage in Group 2, and this difference was statistically significant (p\u0026lt;0.001; p\u0026lt;0.01).\u003c/p\u003e","description":"","filename":"placeholderimage.png","url":"https://assets-eu.researchsquare.com/files/rs-7124194/v1/d58430c911edf433d07b33ae.png"},{"id":95797598,"identity":"ba3809c7-f6ce-406e-86fa-224d2cb6b518","added_by":"auto","created_at":"2025-11-13 08:07:06","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":954468,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7124194/v1/ae74f1a5-a109-4556-8698-ac42bcba9937.pdf"},{"id":91999537,"identity":"7b78cafa-edad-4814-983a-4e0f76d0478d","added_by":"auto","created_at":"2025-09-23 14:13:18","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":16085,"visible":true,"origin":"","legend":"","description":"","filename":"table1.docx","url":"https://assets-eu.researchsquare.com/files/rs-7124194/v1/bcd00d4612a03f0e288eb847.docx"},{"id":91999538,"identity":"09311141-ad53-49b3-aedf-fd87d81a3b10","added_by":"auto","created_at":"2025-09-23 14:13:18","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":15528,"visible":true,"origin":"","legend":"","description":"","filename":"table2.docx","url":"https://assets-eu.researchsquare.com/files/rs-7124194/v1/4bcb1c3a9fc3e275ee055e32.docx"}],"financialInterests":"No competing interests reported.","formattedTitle":"The Effect of stemcell treatment on nephrotoxicity developing after cyclophosphamide treatment","fulltext":[{"header":"Introduction","content":"\u003cp\u003eCyclophosphamide (CTX) is widely used in cancer treatment and has many side effects, primarily nephrotoxicity and hepatotoxicity (1). Today, cyclophosphamide is widely used as a chemotherapeutic agent, alone or in combination. It is used as an immunosuppressant especially in acute and chronic leukemias; ovarian cancers; multiple myeloma; lymphoma; testicular, small cell lung, and breast cancers; as well as organ transplantation; rheumatoid arthritis; systemic lupus erythematosus; and multiple sclerosis (2,3).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe two active metabolites of cyclophosphamide are phosphoramide mustard and acrolein. The antineoplastic effects of cyclophosphamide are related to phosphoramide mustard. It is thought that phosphoramide mustard suppresses cell division by binding to DNA and mediating the immunosuppressive and antitumor effects of cyclophosphamide. The toxic effect of cyclophosphamide is related to its active metabolite, acrolein (4). Acrolein inhibits P-450 by alkylating sulfhydryl groups (5) and metabolizing glutathione via rapid modification of sulfhydryl groups to form mercapturic acid, which is excreted in urine (6). These metabolites cause both hepatic and renal damage. The renal pathological damage process caused by CTX is mediated by apoptosis and necrosis of renal tubular epithelial cells (7), release of inflammatory factors, and inflammatory response (8).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eStem cells are cells that can self-renew, differentiate into multiple cell types, and proliferate to produce and renew different types of tissues and organs. Stem cells are used in the treatment of many diseases (5) (6,7). In addition, stem cell transplantation is performed after CTX in some cancer treatment protocols (8). While research has explored strategies for the treatment of both hepatotoxicity (9,10,11) and nephrotoxicity (12,13,14), we have not come across any reports investigating the efficacy of stem cell therapies in cyclophosphamide treatment. Stem cell therapies are used after cyclophosphamide in the treatment protocol of some cancer diseases (15). In addition, stem cells have paracrine effects by promoting their differentiation capacity into other cells and generating immune regulatory, anti-inflammatory, anti-apoptotic, and anti-oxidative effects (16,17). Stem cells also have analgesic and angiogenic effects (18). Due to the regeneration properties of stem cells, damaged tissues can be renewed and repaired. In this study, we aimed to investigate the efficacy of umbilical cord-derived mesenchymal stem cells in animals with renal damage induced by CTX.\u003c/p\u003e"},{"header":"Materials and Methods","content":"\u003cp\u003e\u003cstrong\u003e\u003cem\u003eFormation of cyclophosphamide-induced\u0026nbsp;\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003ekidney injury\u003cem\u003e\u0026nbsp;model and administration of h-USMSC.\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA total of 18 female Sprague Dawley rats that were 9–10 weeks old and weighed 200–220 g were used in the study. The animals were obtained from the Gazi University Laboratory Animal Breeding and Experimental Research Centre and studied in the same laboratory. The study was approved by the Gazi University Animal Experiments Local Ethics Committee (Approval number: G.Ü.E.T-66332047-604.01-1015251). The animals were randomly divided into 3 groups. Group 1 (control group) received 2 cc 0.9% saline infusion intraperitoneally. For the liver and kidney injury models, Groups 2 and 3 were injected with 50 mg/kg cyclophosphamide (Endoxan, EIP ECZACIBAŞI, Istanbul, Turkey) on the first day, and then 8 mg/kg intraperitoneal cyclophosphamide (CTX) was injected into the animals for 14 days. Group 3 was then injected with 0.6ml×10\u003csup\u003e5\u003c/sup\u003e/μL human Umbilical Cord Mesenchymal Stem Cell (hUC-MCS) intraperitoneally once a week for 2 weeks.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAt the end of the 4th week of the experiment, \u0026nbsp; animals were euthanized by intracardiac blood sampling under xylazine (5 mg/kg, i.m) and ketamine (45 mg/kg, i.m) anesthesia. Kidney and liver tissues were then removed and fixed in formaldehyde.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eHistological examination of rat kidneys\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eKidneys were fixed with 4% paraformaldehyde and embedded in paraffin for pathological analysis. Paraffin blocks were cut into 4-μm thick sections and stained with hematoxylin and eosin (H\u0026amp;E) and caspase.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eElisa\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eWhole blood samples from the study groups were centrifuged at 3500 rpm for 10 minutes to separate the sera. Humor samples were stored in a -80◦C deep freezer until the day of the study together with aqueous humor samples. Serum samples were measured using the BT Lab (Zhejiang, China) brand kit using the sandwich ELISA principle. The experiment was performed according to the instructions of the commercial kit. A standard graph was drawn according to the absorbance in the standard samples, and the absorbance values read in the samples were substituted into this graph to calculate the concentrations.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eKidney function evaluation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTo evaluate kidney function, BUN (blood urea nitrogen), urea, and creatinine levels were checked at 6 weeks in Groups 1, 2 and 3. Histopathologically, the degree of tubular atrophy was examined at four stages (0–25%, 25–50%, 50–75%, and 75–100%) and scored between 0–3. The presence of glomerulosclerosis was divided into 4 stages (0-25%, 25-50%, 50-75%, and 75-100%) and scored between 0–3 according to the percentage of presence in the examined area. Those with and without inflammation were graded as 0 and 1, respectively.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eStatistical Analysis\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eIn this study, the studied data set was statistically compared among three different separate groups based on specific measurement criteria. The Kruskal-Wallis analysis of variance was done to evaluate differences in measurement parameters between group levels. If a difference existed, the Dunnett method was used to determine pairwise comparisons of group levels. The test's critical value was 0.05, and a p-value greater than 0.05 indicated that there was no significant difference between variables.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe variables examined in the study glomerulosclerosis, tubal damage, and inflammation are categorical in nature, and their distributions were compared across three different groups (Control, CTX, and CTX + stem cell). These variables typically have between 2 to 4 levels and exhibit ordinal categorical structure (e.g., scores ranging from 0 to 3). Due to the relatively small sample sizes in each group and the presence of expected cell frequencies below 5 in some contingency tables, the assumptions of the chi-square test could not be met. Therefore, the Fisher’s Exact Test, a more appropriate and sensitive alternative for small sample sizes, was used to assess group differences. Otherwise, a statistical significance was measured between the variables. All analyses were conducted using the R programming language.\u0026nbsp;\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eWhen BUN, creatinine, and urea levels were evaluated biochemically in the three groups, no significant change was observed (Table 1).\u003c/p\u003e\n\u003cp\u003eIn histopathological evaluation, in the Group 1 control group, 3 samples (60%) showed Stage 0 and 2 samples (40%) showed Stage 1 glomerulosclerosis. In the Group 2 cyclophosphamide group, 4 samples (80%) showed Stage 2 and 1 sample (20%) showed Stage 3 glomerulosclerosis. In the Group 3 cyclophosphamide + stem cell therapy group, 5 samples (100%) showed Stage 1 glomerular sclerosis, and the difference was statistically significant (p\u0026lt;0.001). When tubular atrophy was evaluated, in Group 1, 2 samples (40%) showed Stage 0 and 3 samples (60%) showed Stage 1. In Group 2, 3 samples (60%) showed Stage 2 and 2 samples (40%) showed Stage 3. In Group 3, 4 samples (80%) were detected as Stage 1 and 1 sample (20%) as Stage 2. The observed differences were statistically significant (p=0.010).\u003c/p\u003e\n\u003cp\u003eThe presence of inflammation was observed in 2 samples (40%) in Group 1, 5 samples (100%) in Group 2 and 1 sample (20%) in Group 3 and was significantly lower in Group 3. However, this difference was not statistically significant (p=0.068) (Table 2).\u003c/p\u003e\n\u003cp\u003eHistopathological comparison was made between Group 1-control, Group 2-CTX and Group 3-CTX+ stem cell included in the study. In histopathological examination, normal shapes and structures were seen in all areas of the kidney tissues in Group 1. In Group 2, glomeruli shrinkage, Bowman space widening, dilatation, degeneration, and epithelial vacuolization in tubules were observed. In addition, moderate inflammation was observed throughout the entire section. In Group 3, serious regeneration was observed in all areas of the kidney tissue, including an improvement in Bowman spaces; tubular dilatation, epithelial degeneration and vacuolization were also observed to significantly decrease. In caspase-3 staining, normal findings were detected in Group 1, while increased staining was observed in glomeruli and tubular structures in Group 2. In Group 3, a high rate of tubular and glomerular regeneration was observed (Figure 1).\u003c/p\u003e\n\u003cp\u003eGlomerulosclerosis and tubular damage were seen most in Group 2, and this difference was found to be statistically significant (p\u0026lt;0.001; p\u0026lt;0.01) \u003cstrong\u003eFigure 2.\u003c/strong\u003e\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eSince the metabolism enzymes of many drugs are located in the kidneys, these organs are where these agents are excreted from the body and can therefore show toxicity. Cyclophosphamide (CTX) is a drug generally used in chemotherapy, and its metabolites are primarily excreted in the urine. Therefore, it is known that CTX can be toxic to the kidneys. CTX delays the growth of malignant cells due to its toxic metabolites phosphoramide and acrolein. Acrolein inhibits the cellular antioxidant defense cycle and causes the formation of reactive oxygen radicals, including superoxide anions, hydroxyl radicals, and hydrogen peroxide, which cause physiological and morphological changes (19). The formation of free radicals causes the disruption of many signaling pathways, including the inflammation pathway and ultimately organ fibrosis (20). This situation has led to the hypothesis that the effects of CTX can be reduced using antioxidant agents. It is known that the mutagenic and cytotoxic effects of cyclophosphamide are specific to proliferating cells only, and that quiescent cells are relatively protected by damage detection mechanisms. However, cyclophosphamide is known to cause severe side effects in high doses and/or long-term use. In today's nephrology practice, the use of CTX has been significantly restricted. However, it is still used as a steroid-reducing drug in minimal change disease and focal segmental glomerulosclerosis, both in combination with steroids in membranous glomerulonephritis and as the first choice in rapidly progressive glomerulonephritis and certain lupus patients. It is generally recommended to avoid long-term use (21). Although there are restrictions on its use in nephrology practice, cyclophosphamide is used in the treatment of many malignancies. Since significant beneficial effects are observed in allogeneic or autologous stem cell transplantation applied after cyclophosphamide treatment, the question of whether it may have similar effects on damaged kidney tissues has emerged.\u003c/p\u003e\n\u003cp\u003eAs in tumors, damaged tissues secrete various factors that attract stem cell migration via the CXCL12/CXCR4 axis. Factors that promote stem cell migration include interleukin 8 (IL-8) and transforming growth factor-beta 1 (TGF-β1) (22), platelet-derived growth factor (PDGF) (23), fibroblast growth factor 2 (FGF-2) (24), vascular endothelial growth factor (VEGF) (24), and extracellular matrix molecules such as matrix metalloproteinase-2 (MMP-2) (25). The primary reparative mechanisms of stem cells include paracrine effects such as angiogenesis (26), anti-apoptosis (26), anti-fibrosis (27), and immunomodulation (28). It is known that exosomes, which are vesicles derived from stem cells that are 30 to 160 nm in size, play an important role in regulating intercellular communication (29). It is also known that stem cells have the potential to replace damaged mitochondria in damaged cells and increase cell quality (30), therefore their healing effects on damaged tissues were examined in our study.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eThe differences between kidney function tests in the samples were first evaluated. However, no significant difference was found between the groups in terms of BUN, urea, or creatinine levels. It is thought that this situation may be because these markers were measured at the 6th week. In similar studies, kidney functions were evaluated in rats given CTX in a shorter period of time. For example, in Uygun et al., kidney function tests were measured 24 hours after cyclophosphamide administration, and significant increases in creatinine and urea were observed in the CTX arm (31). In a similar study, the protective effects of tolvaptan on CTX treatment were investigated; blood samples were taken one day after CTX administration, and significant increases in creatinine and urea were observed in the CTX arm (32). In a study aiming to reduce the effects of high-dose CTX treatment, the effects of Wuzhi capsules on treatment were investigated; once again, as blood samples were taken at an early stage, urea and creatinine values were found to be significantly higher in the CTX group compared to the control group (33).\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIn many similar studies, urea and creatinine were observed to be significantly higher in the CTX groups compared to the control groups in the samples taken immediately after the completion of the experiment (34,35,36,37). In a study where creatinine, BUN, and urea were measured on the 25th day of cyclophosphamide administration, kidney function tests were found to be significantly higher in the CYS arm (38). In our study, taking the samples at the 6th week made a difference in terms of providing information on the late effects of cyclophosphamide on kidney functions. Although BUN, creatinine, and urea levels were higher in the cyclophosphamide arm at the end of the 6th week, this increase was not statistically significant. This situation can be explained by the fact that the acute kidney injury picture started to improve in rats that had experienced an acute kidney injury when there was no repeated dosing.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTo observe organ integrity in the event of any damage, pathological indicators can be shown by the deterioration of the structural integrity and shape of the organ. It is known that cyclophosphamide directly induces oxidative stress, causes apoptosis and inflammation, and leads to histopathological conditions (39). In our study, via hematoxylin-eosin staining, renal integrity was seen to be impaired: There was shrinkage in the glomeruli, widening in the Bowman spaces, dilatation in the renal tubules, and vacuolization in the epithelium and degeneration, especially in the renal tubules. In addition, moderate inflammation was observed in all sections. The findings are also consistent with previous studies (19,33,34,35,36).\u003c/p\u003e\n\u003cp\u003eIn the group that received stem cell application with the aim of repairing effects on damaged tissues, significant regeneration was observed in the hematoxylin and eosin-stained sections. There was an improvement in glomerular Bowman spaces; and tubular dilatation, epithelial degeneration, and vacuolization had significantly lessened.\u003c/p\u003e\n\u003cp\u003eApoptosis, which is a cell collapse characterized by condensation of the cell membrane, shrinkage of the cell, condensation of chromatin and fragmentation of DNA, occurs as a result of reactive oxygen radicals (40, 41). Caspase-3 is considered the main mediator of apoptosis in cells because it initiates the apoptotic process by activating other caspase enzymes, causing fragmentation of DNA and protein structures and condensation of chromatin (42). In our study, while a normal appearance was detected with caspase staining in the control group, a significantly increased uptake in glomerular and tubular structures was observed in the CTX group, and tubular and glomerular regeneration was observed in the CTX+stem cell group. This situation was observed in our study, similar to existing studies (19, 42, 43).\u003c/p\u003e\n\u003cp\u003eToday, hUC-MCS is used in the treatment of diseases with nephropathy, such as diabetes mellitus and systemic lupus erythematosus. When applied in the treatment of diabetic nephropathy, it has been observed to reduce the expression of inflammatory cytokines; increase the number of Sertoli cells and rearrange their proteins; and increase the expression of anti-apoptotic proteins in the kidneys (44). In studies conducted in diabetic mice, it has been observed that BUN and 24-hour urine albumin excretion significantly decrease after hUC-MCS application (45). In lupus nephritis, it is thought that hUC-MCS migration to the kidney is accelerated by CXCL10 synthesized by increased glomerular vascular endothelial cells via the FN-γ/IRF1-KPNA4 pathway. The negative effect of therapeutic effects on the blockade of the CXCL10-CXCR3 pathway also supports this view (46). It has also been shown that hUC-MCSs improve lupus nephritis by affecting T and B cell responses (47).\u003c/p\u003e\n\u003cp\u003eThe use of hUC-MCS treatment in diseases with nephropathy and its beneficial effects shed light on its use in primary and secondary nephropathies. The waste material, a human umbilical cord, was obtained non-invasively; the lack of ethical issues provides an advantage over other sources of stem cells. In addition, the neonatal age of the donor creates a difference in terms of stem cell potency. In our study, it was observed that cyclophosphamide improved the pathological effects and provided significant morphological improvement. These findings suggest that its use in drug-related nephropathies may be beneficial, indicating that it may be worth trying in other nephrological diseases.\u003c/p\u003e\n\u003cp\u003eThe factors affecting the results of the study include the reparative effects of the stem cells administered for therapeutic purposes on the kidney tissue, the duration and frequency of treatment, the number of cells administered for therapeutic purposes, the selected stem cell source, and even the donor selection. Another factor affecting the results is the time elapsed after administration of the stem cell treatment. Changes in kidney tissue after stem cell transplantation may also vary depending on the time of euthanasia. We believe that these factors explain the different results among studies to some extent. Therefore, more studies are needed.\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003ePermanent organ damage due to cytotoxic agents used for different purposes has the potential to create serious problems in the future. In this context, the possible nephrotoxic effects of cyclophosphamide, which is used in many cancer treatments, were examined in this study and shown to cause pathologies resulting in glomerulosclerosis and tubular damage. Although no early deviations were detected in laboratory parameters considered as clinical indicators, it is possible that possible failures may occur in the long term. In this context, it has been shown that stem cell applications given together reduce the formation of glomerulosclerosis and tubular damage, and it is thought that this effect may be effective in long-term survival. In the future, it can be expected that these applications will be beneficial in terms of effectiveness within classical protocols in cost-effectiveness studies.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eConflict of Interest:\u003c/strong\u003e There is no conflict of interest between the authors. All authors read and approved the final version of the manuscript\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAttestation Statement:\u003c/strong\u003e Animal experiment study\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding: No funding.\u003c/strong\u003e\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompliance with Ethical Standards:\u0026nbsp;\u003c/strong\u003eWritten approval from the Gazi University Ethics Committee, was obtained for the study. \u0026nbsp;\u0026nbsp;\u003cstrong\u003eThe study was approved by Gazi University Animal Experiments Local Ethics Committee (Approval number: G.Ü.E.T-66332047-604.01-1015251).\u003c/strong\u003e All authors have approved the manuscript submission, and the manuscript has not been published. It is not being considered for publication elsewhere, in whole or in part, in any language.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eAll data generated or analysed during this study are included in this published article and its supplementary information files and \u0026nbsp; the datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.\u003c/p\u003e\n\u003cp\u003eConsent for Publication\u0026nbsp;:\u0026nbsp;Not Applicable\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor contribution.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eMuzaffer ÇAYDERE- Pathological examination of tissues and Data collection\u003c/em\u003e\u003cem\u003e\u0026nbsp;writer\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eAytaj JAFARZADE, -Conception, design,writer , supervision, literature review\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eFeyza Bayrakdar Çağlayan-\u0026nbsp;\u003c/em\u003e\u003cem\u003eConception, design,writer , supervision, literature review\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eElvan ANADOL \u0026nbsp;- Animal \u0026nbsp; prosessing and data collection\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eDurmuş BURGUCU- Preparation and application of hucMSCs and Data collection\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eCanan YILMAZ- Study and analysis of blood samples and Data Collection\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eSemih ERGİŞİ - Statistical analysis and interpretation\u0026nbsp;\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eTamer M. MUNGAN\u003csup\u003e-\u0026nbsp;\u003c/sup\u003eCritical reviewing\u0026nbsp;\u003c/em\u003e\u003c/p\u003e"},{"header":"References","content":"\u003col start=\"1\" type=\"1\"\u003e\n \u003cli\u003eJiang X, Ren Z, Zhao B, Zhou S, Ying X, Tang Y. Ameliorating Effect of Pentadecapeptide Derived from \u003cem\u003eCyclina sinensis\u003c/em\u003e on Cyclophosphamide-Induced Nephrotoxicity. Mar Drugs. 2020 Sep 9;18(9):462. doi: 10.3390/md18090462.\u003c/li\u003e\n \u003cli\u003ePerini P, Calabrese M, Rinaldi L, Gallo P (2007) The safety profile of cyclophosphamide in multiple sclerosis therapy. Expert Opin Drug Saf 6:183\u0026ndash;190\u003c/li\u003e\n \u003cli\u003eUber WE, Self SE, Van Bakel AB, Pereira NL (2007) Acute antibody-mediated rejection following heart transplantation. Am J Transplant 7:2064\u0026ndash;2074\u003c/li\u003e\n \u003cli\u003eCengiz M, Yeşildağ \u0026Ouml;, Ayhancı A. Siklofosfamid Nedenli Hematoksisite \u0026Uuml;zerine Karvakrol\u0026uuml;n Sitoprotektif Etkileri. T\u0026Uuml;TAD. Haziran 2018;5(2):125-130. doi:10.19159/tutad.378717\u003c/li\u003e\n \u003cli\u003eZarei, Mahsa, and T. Shivanandappa. \u0026quot;Amelioration of cyclophosphamide-induced hepatotoxicity by the root extract of Decalepis hamiltonii in mice.\u0026quot; \u003cem\u003eFood and chemical toxicology\u003c/em\u003e 57 (2013): 179-184.\u003c/li\u003e\n \u003cli\u003eMohammad, Mohammad K., et al. \u0026quot;Acrolein cytotoxicity in hepatocytes involves endoplasmic reticulum stress, mitochondrial dysfunction and oxidative stress.\u0026quot; \u003cem\u003eToxicology and applied pharmacology\u003c/em\u003e 265.1 (2012): 73-82.\u003c/li\u003e\n\u003c/ol\u003e\n\u003col start=\"7\"\u003e\n \u003cli\u003eRehman MU, Tahir M, Ali F, Qamar W, Lateef A, Khan R, Quaiyoom A, Oday-O-Hamiza, Sultana S. Cyclophosphamide-induced nephrotoxicity, genotoxicity, and damage in kidney genomic DNA of Swiss albino mice: the protective effect of Ellagic acid. Mol Cell Biochem. 2012 Jun;365(1-2):119-27.\u003c/li\u003e\n\u003c/ol\u003e\n\u003col start=\"8\" type=\"1\"\u003e\n \u003cli\u003eKang X, Jing M, Zhang G, He L, Hong P, Deng C. The Ameliorating Effect of Plasma Protein from \u003cem\u003eTachypleus tridentatus\u003c/em\u003e on Cyclophosphamide-Induced Acute Kidney Injury in Mice. Mar Drugs. 2019 Apr 15;17(4):227\u003c/li\u003e\n \u003cli\u003eCuce G, \u0026Ccedil;etinkaya S, Koc T, Esen HH, Limandal C, Balcı T, Kalkan S, Akoz M. Chemoprotective effect of vitamin E in cyclophosphamide-induced hepatotoxicity in rats. Chem Biol Interact. 2015 May 5;232:7-11. doi: 10.1016/j.cbi.2015.02.016.\u003c/li\u003e\n \u003cli\u003eNafees S, Rashid S, Ali N, Hasan SK, Sultana S. Rutin ameliorates cyclophosphamide induced oxidative stress and inflammation in Wistar rats: role of NF\u0026kappa;B/MAPK pathway. Chem Biol Interact. 2015 Apr 25;231:98-107. doi: 10.1016/j.cbi.2015.02.021.\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eMohammed MJ, Tadros MG, Michel HE. Geraniol protects against cyclophosphamide-induced hepatotoxicity in rats: Possible role of MAPK and PPAR-\u0026gamma; signaling pathways. Food Chem Toxicol. 2020 May;139:111251. doi: 10.1016/j.fct.2020.111251\u003c/li\u003e\n \u003cli\u003eLiu Q, Lin X, Li H, Yuan J, Peng Y, Dong L, Dai S. Paeoniflorin ameliorates renal function in cyclophosphamide-induced mice via AMPK suppressed inflammation and apoptosis. Biomed Pharmacother. 2016 Dec;84:1899-1905\u003c/li\u003e\n \u003cli\u003eShi M, Pei H, Sun L, Chen W, Zong Y, Zhao Y, Du R, He Z. Optimization of the Flavonoid Extraction Process from the Stem and Leaves of Epimedium Brevicornum and Its Effects on Cyclophosphamide-Induced Renal Injury. Molecules. 2023 Dec 29;29(1):207.\u0026nbsp;\u003c/li\u003e\n \u003cli\u003ePramita Chakraborty, Ugir Hossain Sk, et al. \u0026quot;Modulation of cyclophosphamide-induced cellular toxicity by diphenylmethyl selenocyanate in vivo, an enzymatic study.\u0026quot; \u003cem\u003eJ Journal of Cancer Molecules\u003c/em\u003e 4.6 (2009): 183-189.\u003c/li\u003e\n \u003cli\u003eWei X, Wei Y. Stem cell mobilization in multiple myeloma: challenges, strategies, and current developments. Ann Hematol. 2023 May;102(5):995-1009.\u003c/li\u003e\n \u003cli\u003eBrown C, McKee C, Bakshi S, Walker K, Hakman E, Halassy S, Svinarich D, Dodds R, Govind CK, Chaudhry GR. Mesenchymal stem cells: Cell therapy and regeneration potential. J Tissue Eng Regen Med. 2019 Sep;13(9):1738-1755. doi: 10.1002/term.2914.\u003c/li\u003e\n \u003cli\u003eHan Y, Li X, Zhang Y, Han Y, Chang F, Ding J. Mesenchymal Stem Cells for Regenerative Medicine. Cells. 2019 Aug 13;8(8):886. doi: 10.3390/cells8080886.\u003c/li\u003e\n \u003cli\u003eErceg Ivko\u0026scaron;ić I, Fure\u0026scaron; R, Ćosić V, Mikelin N, Bulić L, Dobranić D, Brlek P, Primorac D. Unlocking the Potential of Mesenchymal Stem Cells in Gynecology: Where Are We Now? J Pers Med. 2023 Aug 13;13(8):1253.\u003c/li\u003e\n \u003cli\u003eCaglayan C, Temel Y, Kandemir FM, Yildirim S, Kucukler S. Naringin protects against cyclophosphamide-induced hepatotoxicity and nephrotoxicity through modulation of oxidative stress, inflammation, apoptosis, autophagy, and DNA damage. \u003cem\u003eEnviron Sci Pollut Res Int\u003c/em\u003e. 2018;25(21):20968-20984. doi:10.1007/s11356-018-2242-5\u003c/li\u003e\n \u003cli\u003e\u0026nbsp;Meng X.-M., Nikolic-Paterson D. J., Lan H. Y. Inflammatory processes in renal fibrosis. Nature Reviews Nephrology . 2014;10(9):493\u0026ndash;503. doi: 10.1038/nrneph.2014.114.)\u003c/li\u003e\n \u003cli\u003ePonticelli, C., Escoli, R., \u0026amp; Moroni, G. (2018). Does cyclophosphamide still play a role in glomerular diseases?. \u003cem\u003eAutoimmunity Reviews\u003c/em\u003e, \u003cem\u003e17\u003c/em\u003e(10), 1022-1027\u003c/li\u003e\n \u003cli\u003e\u003cem\u003ede Araujo Farias V, Carrillo-Galvez AB, Martin F, Anderson P. TGF-beta and mesenchymal stromal cells in regenerative medicine, autoimmunity and cancer. Cytokine Growth Factor Rev. 2018;43:25\u0026ndash;37. doi: 10.1016/j.cytogfr.2018.06.002\u003c/em\u003e\u003c/li\u003e\n \u003cli\u003e\u003cem\u003eDing W, et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood. 2010;116:2984\u0026ndash;2993. doi: 10.1182/blood-2010-02-269894\u003c/em\u003e.\u003c/li\u003e\n \u003cli\u003e\u003cem\u003eRitter E, et al. Breast cancer cell-derived fibroblast growth factor 2 and vascular endothelial growth factor are chemoattractants for bone marrow stromal stem cells. Ann. Surg. 2008;247:310\u0026ndash;314. doi: 10.1097/SLA.0b013e31816401d5\u003c/em\u003e.\u003c/li\u003e\n \u003cli\u003eC\u003cem\u003eronwright G, et al. Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res. 2005;65:2207\u0026ndash;2215. doi: 10.1158/0008-5472.CAN-04-188\u003c/em\u003e\u003c/li\u003e\n \u003cli\u003eTeng X, Wang Z, Wang X. Enhancing angiogenesis and inhibiting apoptosis: evaluating the therapeutic efficacy of bone marrow mesenchymal stem cell-derived exosomes in a DHEA-induced PCOS mouse model. J Ovarian Res. 2024 Jun 5;17(1):121. doi: 10.1186/s13048-024-01445-w.\u003c/li\u003e\n \u003cli\u003eVanderstichele S, Vranckx JJ. Anti-fibrotic effect of adipose-derived stem cells on fibrotic scars. World J Stem Cells. 2022 Feb 26;14(2):200-213. doi: 10.4252/wjsc.v14.i2.200.\u003c/li\u003e\n \u003cli\u003eLi J, Wu M, He L. Immunomodulatory effects of mesenchymal stem cell therapy in chronic kidney disease: a literature review. BMC Nephrol. 2025 Mar 3;26(1):107. doi: 10.1186/s12882-025-04029-y.\u003c/li\u003e\n \u003cli\u003eTan F, Li X, Wang Z, Li J, Shahzad K, Zheng J. Clinical applications of stem cell-derived exosomes. Signal Transduct Target Ther. 2024 Jan 12;9(1):17. doi: 10.1038/s41392-023-01704-0.\u003c/li\u003e\n \u003cli\u003eZhang, C., Meng, Y. \u0026amp; Han, J. Emerging roles of mitochondrial functions and epigenetic changes in the modulation of stem cell fate. Cell. Mol. Life Sci. 81, 26 (2024). https://doi.org/10.1007/s00018-023-05070-6\u003c/li\u003e\n \u003cli\u003eUyumlu AB, Satılmış B, Atıcı B, Taşlıdere A. Phenethyl isothiocyanate protects against cyclophosphamide-induced nephrotoxicity via nuclear factor E2-related factor 2 pathway in rats. Exp Biol Med (Maywood). 2023 Jan;248(2):157-164.\u003c/li\u003e\n \u003cli\u003eEl‐Shabrawy, M., Mishriki, A., Attia, H., Emad Aboulhoda, B., Emam, M., \u0026amp; Wanas, H. (2020). Protective effect of tolvaptan against cyclophosphamide‐induced nephrotoxicity in rat models. \u003cem\u003ePharmacology Research \u0026amp; Perspectives\u003c/em\u003e, \u003cem\u003e8\u003c/em\u003e(5), e00659.\u003c/li\u003e\n \u003cli\u003eChen, L., Xiong, X., Hou, X., Wei, H., Zhai, J., Xia, T., ... \u0026amp; Chen, W. (2019). Wuzhi capsule regulates chloroacetaldehyde pharmacokinetics behaviour and alleviates high‐dose cyclophosphamide‐induced nephrotoxicity and neurotoxicity in rats. \u003cem\u003eBasic \u0026amp; Clinical Pharmacology \u0026amp; Toxicology\u003c/em\u003e, \u003cem\u003e125\u003c/em\u003e(2), 142-151.\u003c/li\u003e\n \u003cli\u003eMohsin N, Akhtar MS, Alkahtani SA, et al. Nephroprotective Effect of Bergapten Against Cyclophosphamide-Mediated Renal Stress, Inflammation, and Fibrosis in Wistar Rats: Probable Role of NF-kB and TGF-\u0026beta;1 Signaling Molecules. ACS Omega. 2024 Apr 12;9(16):18296-18303.\u003c/li\u003e\n\u003c/ol\u003e\n\u003col start=\"35\"\u003e\n \u003cli\u003eSalama, R. M., Nasr, M. M., Abdelhakeem, J. I., Roshdy, O. K., \u0026amp; ElGamal, M. A. (2022). Alogliptin attenuates cyclophosphamide-induced nephrotoxicity: a novel therapeutic approach through modulating MAP3K/JNK/SMAD3 signaling cascade. \u003cem\u003eDrug and Chemical Toxicology\u003c/em\u003e, \u003cem\u003e45\u003c/em\u003e(3), 1254-1263.\u003c/li\u003e\n \u003cli\u003e\u0026nbsp;Gunes, S., Sahinturk, V., Uslu, S., Ayhanci, A., Kacar, S., \u0026amp; Uyar, R. (2018). Protective effects of selenium on cyclophosphamide-induced oxidative stress and kidney injury. \u003cem\u003eBiological trace element research\u003c/em\u003e, \u003cem\u003e185\u003c/em\u003e, 116-123.\u003c/li\u003e\n \u003cli\u003eWanas, H., El‐Shabrawy, M., Mishriki, A., Attia, H., Emam, M., \u0026amp; Aboulhoda, B. E. (2021). Nebivolol protects against cyclophosphamide‐induced nephrotoxicity through modulation of oxidative stress, inflammation, and apoptosis. \u003cem\u003eClinical and Experimental Pharmacology and Physiology\u003c/em\u003e, \u003cem\u003e48\u003c/em\u003e(5), 811-819.)\u003c/li\u003e\n\u003c/ol\u003e\n\u003col start=\"38\" type=\"1\"\u003e\n \u003cli\u003eAlsaidi, Z. Z., Humaish, H. H., \u0026amp; Alasadi, A. (2022). Toxic effects of cyclophosphamide on hepatic and kidney tissues in albino mice model. \u003cem\u003eResearch Journal of Pharmacy and Technology\u003c/em\u003e, \u003cem\u003e15\u003c/em\u003e(10), 4655-4659.)\u003c/li\u003e\n \u003cli\u003eCetinavci D.; Yenilmez D.; Yenilmez E.; Firuze Bıyık A.; Alver A.; Sağlam N. Rosmarinik asidin sı\u0026ccedil;anlarda siklofosfamid ile ind\u0026uuml;klenen nefrotoksisite \u0026uuml;zerine etkileri. Cukurova Med. J. 2023, 48 (3), 902\u0026ndash;910. 10.17826/CUMJ.1317508.\u003c/li\u003e\n \u003cli\u003eRenehan AG, Booth C, Potten CS. What is apoptosis, and why is it important? BMJ. 2001 Jun 23;322(7301):1536-8. doi: 10.1136/bmj.322.7301.1536.\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eKim S, Lee I, Baek H, et al. Mechanism for the protective effect of diallyl disulfide against cyclophosphamide acute urotoxicity in rats. Food Chem Toxicol. 2014;64:110-118.\u003c/li\u003e\n \u003cli\u003eFouad A, Qutub H, Al-Melhim W. Punicalagin alleviates hepatotoxicity in rats challenged with cyclophosphamide. Environ Toxicol Pharmacol. 2016;45:158-162\u003c/li\u003e\n\u003c/ol\u003e\n\u003col start=\"43\"\u003e\n \u003cli\u003eSinanoglu O, Yener AN, Ekici S, Midi A, Aksungar FB (2012) The protective effects of spirulina in cyclophosphamide induced nephrotoxicity and urotoxicity in rats. Urology 80:1392\u0026ndash;13e1. https:// doi.org/10.1016/j.urology.2012.06.053\u003c/li\u003e\n\u003c/ol\u003e\n\u003col start=\"44\" type=\"1\"\u003e\n \u003cli\u003eXiang E, Han B, Zhang Q, Rao W, Wang Z, Chang C, Zhang Y, Tu C, Li C, Wu D. Human umbilical cord-derivedmesenchymal stem cells prevent the progression of early diabetic nephropathythrough inhibiting inflammation and fibrosis. Stem Cell Res Ther. 2020;11(1):336\u0026ndash;350. doi: 10.1186/s13287-020-01852-y.)\u003c/li\u003e\n\u003c/ol\u003e\n\u003col start=\"45\"\u003e\n \u003cli\u003eXian Y, Lin Y, Cao C, Li L, Wang J, Niu J, YunleiGuo YS, Wang Y, Wang W. Protective effect of umbilical cord mesenchymal stem cells combined with resveratrol against renal podocyte damage in NOD mice. Diabetes Res Clin Pract. 2019;156:107755\u0026ndash;107764. doi: 10.1016/j.diabres.2019.05.034\u003c/li\u003e\n\u003c/ol\u003e\n\u003col start=\"46\" type=\"1\"\u003e\n \u003cli\u003eZhang, Q., Shan, Y., Shen, L., Ni, Q., Wang, D., Wen, X., Xu, H., Liu, X., Zeng, Z., Yang, J., Wang, Y., Liu, J., Su, Y., Wei, N., Wang, J., Sun, L., Wang, G., \u0026amp; Zhou, F. (2024). Renal remodeling by CXCL10-CXCR3 axis-recruited mesenchymal stem cells and subsequent IL4I1 secretion in lupus nephritis. \u003cem\u003eSignal transduction and targeted therapy\u003c/em\u003e, \u003cem\u003e9\u003c/em\u003e(1), 325. https://doi.org/10.1038/s41392-024-02018-5)\u003c/li\u003e\n\u003c/ol\u003e\n\u003col start=\"47\"\u003e\n \u003cli\u003eLi, C., Wu, F., Mao, J., Wang, Y., Zhu, J., Hong, K., Xie, H., Zhou, X., Tian, J., \u0026amp; Wen, C. (2024). Mesenchymal stem cells-derived extracellular vesicles ameliorate lupus nephritis by regulating T and B cell responses. \u003cem\u003eStem cell research \u0026amp; therapy\u003c/em\u003e, \u003cem\u003e15\u003c/em\u003e(1), 216. https://doi.org/10.1186/s13287-024-03834-w\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003eTable 1 and 2 are available in the Supplementary Files section.\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-7124194/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7124194/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eObjectives\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study examines the effects of cyclophosphamide, a cancer treatment that also functions as a cytotoxic agent, on the nephrotic system. The extent to which stem cell applications can be effective in preventing nephrotoxicity caused by agents is also a subject of investigation. The extent to which the nephrotoxic effects detected in the animal model treated with cyclophosphamide can be prevented by stem cell application will be investigated.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMaterial and Methods\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA total of 18 Sprague Dawley rats were included in the study, divided into 3 groups. Group 1 consisted of the control group, which received intraperitoneal (IP) saline injection. Group 2-cyclophosphamide and Group 3-cyclophosphamide + stem cell was administered IP cyclophosphamide (50 mg/kg cyclophosphamide on the first day and then 8 mg/kg intraperitoneally for 14 days) to create a nephrotoxicity model. Group 3-cyclophosphamide + stem cell also received weekly hUCMSC 10*6 IP for 2 weeks. 4 weeks after the treatment, the animals were euthanized, their kidney tissues were histopathologically and immunohistochemically evaluated, and their blood values ​​were biochemically evaluated.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResult\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIn histopathological examination, glomerulosclerosis and tubular damage were seen the most in Group 2, and this difference was found to be statistically significant (p\u0026lt;0.001 and p\u0026lt;0.01). However, no statistically significant difference was observed in terms of inflammation in the kidney tissues (p=0.068). No significant change was observed in the biochemically evaluated BUN, creatinine, or urea levels in all three groups (p\u0026lt;0.8; p\u0026lt;0.141; p\u0026lt;0.8).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIn light of the current information, human Umbilical Cord Mesenchymal Stem Cell (hUC-MCS) has been demonstrated to reduce the nephrotoxicity caused by cyclophosphamide given for cytotoxic purposes on the kidney and exhibit regenerative effects. Our findings create new hope for the use of stem cell therapies in the field of kidney diseases.\u003c/p\u003e","manuscriptTitle":"The Effect of stemcell treatment on nephrotoxicity developing after cyclophosphamide treatment","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-09-23 14:13:13","doi":"10.21203/rs.3.rs-7124194/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"0f921cdf-5a02-4b48-9925-300b67509982","owner":[],"postedDate":"September 23rd, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-11-11T11:24:17+00:00","versionOfRecord":[],"versionCreatedAt":"2025-09-23 14:13:13","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7124194","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7124194","identity":"rs-7124194","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}